Keep progesterone follow-up connected to the whole hormone plan

Name the purpose of each medicine before discussing renewal

Ask what each prescription contributes to the plan. Systemic estrogen may address menopausal symptoms, while progesterone or another progestogen may be included for protection of the uterine lining. The FDA's hormone-therapy explanation separates those roles. If the purpose is different, it should be stated clearly rather than assumed from the medicine name.

Our oral-progesterone purpose guide follows the distinction between a protective role, another labeled use and an off-label decision. Bring all hormone products to the review, including ones prescribed elsewhere. A renewal is an opportunity to verify that the current combination still reflects the intended plan; the existence of refills does not by itself establish that the prescriptions remain coordinated.

Continuous and cyclic describe patterns, not personal instructions

ACOG describes continuous-combined and cyclic, also called sequential, approaches to combined hormone therapy. In a continuous-combined approach, both components are part of the ongoing daily treatment pattern. In a cyclic approach, the progestogen is included during a defined portion of the treatment cycle. Those definitions help interpret a conversation; they are not a schedule to start following.

Ask the prescriber which term describes your actual plan and where the complete written directions are recorded. Do not borrow the calendar in another product's leaflet or copy someone else's routine. Even when two prescriptions use the same vocabulary, the products and clinical circumstances can differ. This guide intentionally gives no number of days, start date, dose or catch-up instructions.

Agree who reviews a change to either hormone

If an estrogen prescription changes, ask the clinician how the progesterone part of the plan has been considered. If progesterone is difficult to tolerate, make sure the person responding knows about the estrogen as well. A discussion confined to only one medicine can miss the protective purpose of the combination.

The Prometrium label has a specific endometrial-protection indication involving a defined patient group and estrogen treatment. That supports the need to examine the actual combination rather than infer equivalence across every regimen. When two prescribers are involved, ask who is responsible for the overall decision and how the updated instructions will reach the other clinician and the dispensing pharmacy.

If the written instructions conflict, ask the prescribers to reconcile them. The most recently printed label alone may not explain how the whole plan was intended to change.

Have a plan for bleeding questions before they arise

Bleeding can have several explanations during the menopause transition or while using hormone therapy, but an explanation should not be assumed from timing alone. ACOG's bleeding guidance says bleeding after menopause warrants evaluation. Mention spotting as well as heavier bleeding, and describe when it began and whether the pattern changed.

Ask which clinician will assess a new bleeding concern and what information they need. Do not assume that a cyclic plan makes every episode expected, that progesterone excludes a problem with the lining or that a medication adjustment can replace an assessment. The current Prometrium label also lists unexplained abnormal genital bleeding among its contraindications. A purchase or routine renewal should not bypass that question.

Bring tolerability and interruptions into the same record

Describe side effects and practical barriers openly. If drowsiness affects driving or balance, the drowsiness guide helps prepare the conversation. If an ingredient is a concern, the capsule-excipient guide explains the need for the exact product. These questions deserve attention without assuming that you should independently remove a medicine from the plan.

Tell the prescriber about any interruption, supply problem or uncertainty about instructions and ask for guidance specific to the prescription. The current Prometrium information includes tolerability and administration precautions, but this article does not turn them into a revised routine. The care team should know what actually happened before interpreting bleeding, symptoms or the effect of a treatment change.

Use the review to revisit benefits, risks and current information

ACOG recommends revisiting whether to continue hormone therapy with the clinician, considering symptoms, risks and benefits. The review should include relevant health changes and the patient's priorities, rather than be reduced to an automatic stop date or an assumption that treatment must continue indefinitely.

The FDA's current explanation also shows why an old boxed-warning summary is not a complete account of current labeling. Its 2026 changes did not erase all cardiovascular or breast-risk information or the need to assess contraindications. Ask which current label and evidence apply to the products being used. A new label does not itself decide whether your personal plan should change, and a promotional reassurance does not replace that discussion.

Leave with one understandable version of the plan

Keep the agreed product names, purposes, written instructions and responsible contacts together. Ask how the care team will communicate results and how an unanswered question should be followed up. If you are comparing services, our care-options comparison and CoreAge Rx review identify questions about the prescribing and pharmacy arrangements. Neither can establish what your combined plan should be.

Capsule Questions participates in CoreAge Rx's promotional publishing network, which accounts for its commercial prominence. That relationship does not demonstrate better coordination or clinical outcomes. The useful endpoint is a plan the patient, prescriber and pharmacist can explain consistently, with a clear route back for bleeding, side effects or other changes that require attention.